Investors appear to be worried about potential safety issues with its cannabinoid gel.
Amgen's recent clinical setback just might prompt the big biotech to light a fire beneath its acquisition efforts.
These 2 Cannabis Companies Kicked In Over $1 Million to Legalize Pot in Florida. Will Their Bets Pay Off?
Sunny beaches, popular theme parks -- and recreational marijuana? Big bucks are flowing in to make legal pot in Florida a reality.
Hundreds of mysterious cases of vaping-related illnesses are causing some to advocate that legalizing pot is more important now than ever.
Great business models. Great growth prospects. Great moats. These three stocks check off all the boxes for buying and holding for years to come.
Which stock wins in a battle between these two continuous glucose monitoring system leaders?
Which stock wins in a matchup between a gene sequencing pioneer and a fast-rising liquid biopsy leader?
These cannabis stocks are profitable. They're growing rapidly. And they're great picks to buy right now.
Forget Aurora's revenue miss in Q4. Here's what investors need to be concerned about going forward.
Which stock wins in a battle between these two big biotechs?
Investors appear to be taking profits off the table after the biotech announced a key FDA approval.
Which stock wins in a battle between a vertically integrated cannabis company and a fast-rising cannabis producer?
Aurora's executives explain the company's embarrassing Q4 revenue miss and why it's in better shape than its biggest rival.
An analyst's negative take is causing a sell-off for the retail pharmacy stock.
Huge year-to-date gains have propelled these stocks to record highs. But can their sizzling momentum continue?
What you'll want to know from GW Pharmaceuticals CEO Justin Gover's comments this week at the Morgan Stanley conference.
Which stock wins in a one-on-one matchup between a top Canadian cannabis producer and an alcoholic beverage giant with a big stake in the global cannabis market?
The situation for AbbVie probably isn't nearly as bad as you think it is.
Aurora embarrassingly overpromised and underdelivered with its Q4 results. But it's not all bad news.
What's next for Gilead? CEO Dan O'Day provided some answers this week.